PET scan images showing presence of target enzyme dCK in normal mice (row A), and lupus diseased mice (row B).
Trethera Receives Grant from National Institute of Allergy and Infectious Diseases for the Advancement of TRE-515 in Lupus
June 27, 2023 11:14 ET | Trethera Corporation
LOS ANGELES, June 27, 2023 (GLOBE NEWSWIRE) -- Trethera Corporation, a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment...
exagen-logo-440x386-1.jpg
Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus
May 16, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE® Lupus are a contracted covered...
Exagen logo_440x386 (1).jpg
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET | Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Fifth Update of ACR
Fifth Update of ACR COVID-19 Vaccine Guidance Supports Fourth Doses for High-Risk Rheumatic Disease Patients
February 02, 2022 10:49 ET | American College of Rheumatology
Atlanta, Feb. 02, 2022 (GLOBE NEWSWIRE) -- The American College of Rheumatology has issued an updated version of its COVID-19 Vaccine Clinical Guidance for Patients with Rheumatic and...
Exagen logo_440x386 (1).jpg
Exagen Inc. Reports Third Quarter 2021 Results
November 10, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended September 30, 2021....
Exagen logo_440x386 (1).jpg
Exagen Inc. Expands Coverage with Inland Empire Health Plan, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE Lupus
October 27, 2021 08:25 ET | Exagen Inc.
SAN DIEGO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today that AVISE® CTD and AVISE Lupus are a contracted covered...
Exagen logo_440x386 (1).jpg
Exagen Showcases Eight Scientific Presentations at ACR’s Virtual Annual Meeting in November 2021
October 21, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today it will be presenting new scientific research at the...
Exagen logo_440x386 (1).jpg
Exagen Inc. to Participate in the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference
September 13, 2021 16:15 ET | Exagen Inc.
SAN DIEGO, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Cantor Fitzgerald Virtual Global...
ACR Webinar: Reprodu
ACR Webinar: Reproductive Health & Rheumatic Disease
August 24, 2021 16:45 ET | American College of Rheumatology
Atlanta, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Rheumatic diseases are lifelong conditions that affect over 54 million Americans, often during their childbearing years. Rheumatic diseases...
Exagen_Full_RGB_Yahoo_600x216.png
Exagen Inc. Reports Second Quarter 2021 Results
August 09, 2021 16:05 ET | Exagen Inc.
SAN DIEGO, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended June 30, 2021. ...